Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
January 2025
New to GT20029? There is a guide in the encyclopedia. Read the guide → Studysummary This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups. Our plain-language summary of this paper — not a Tressless recommendation.
The study evaluated the efficacy and safety of topical GT20029 in 180 male patients with androgenetic alopecia through a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. Participants were divided into groups receiving different concentrations and frequencies of GT20029 or a placebo. The results showed variations in hair growth metrics, such as terminal hair to vellus hair ratio and total hair count, across the different treatment groups. All participants had a history of androgenetic alopecia, with varying disease durations. The study provides insights into the potential of GT20029 as a treatment for hair loss, though specific efficacy outcomes are not detailed in the provided data.
